[{"orgOrder":0,"company":"LG Chem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tigulixostat","moa":"Xanthine oxidase","graph1":"Rheumatology","graph2":"Phase III","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"LG Chem \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"LG Chem \/ Not Applicable"},{"orgOrder":0,"company":"LG Chem","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Tigulixostat","moa":"","graph1":"Rheumatology","graph2":"Phase III","graph3":"LG Chem","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0.10000000000000001,"dosageForm":"Tablet","sponsorNew":"LG Chem \/ Innovent Biologics","highestDevelopmentStatusID":"10","companyTruncated":"LG Chem \/ Innovent Biologics"}]

Find Clinical Drug Pipeline Developments & Deals for Tigulixostat

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : LC350189 (tigulixostat) is a novel xanthine oxidase inhibitor targeting the reduction of uric acid in purine metabolism, by inhibiting the activity of xanthine oxidase.

                          Brand Name : LC350189

                          Molecule Type : Small molecule

                          Upfront Cash : $10.0 million

                          December 14, 2022

                          Lead Product(s) : Tigulixostat

                          Therapeutic Area : Rheumatology

                          Highest Development Status : Phase III

                          Sponsor : Innovent Biologics

                          Deal Size : $95.5 million

                          Deal Type : Collaboration

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Results from US Phase 2 clinical trial—primary end point set at a challenging level confirmed the potential of LC350189 (tigulixostat) as a new gout treatment distinguished from pre-existing drugs, while also demonstrating safety similar to that of the...

                          Brand Name : LC350189

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 03, 2022

                          Lead Product(s) : Tigulixostat

                          Therapeutic Area : Rheumatology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank